Literature DB >> 14584077

Skull base and nonskull base chordomas: clinicopathologic and immunohistochemical study with special reference to nuclear pleomorphism and proliferative ability.

Takahiko Naka1, Carsten Boltze, Amir Samii, Christian Herold, Helmut Ostertag, Yukihide Iwamoto, Yoshinao Oda, Masazumi Tsuneyoshi, Doerthe Kuester, Albert Roessner.   

Abstract

BACKGROUND: To the authors' knowledge, little is known regarding the relation between the proliferative ability and clinicopathologic parameters in skull base chordomas (SBCs) and nonskull base chordomas (NSBCs).
METHODS: The authors investigated 122 conventional chordomas for their clinicopathologic parameters, proliferative ability (MIB-1 labeling index [LI]) and clinical outcome.
RESULTS: Primary NSBCs were found to affect more elderly patients and demonstrated a higher MIB-1 LI compared with primary SBCs. Mitosis was more commonly noted in recurrent NSBCs compared with primary NSBCs. Apoptosis was more frequent in elderly patients than in younger patients with regard to both SBCs and NSBCs. Apoptosis also was found to be correlated with necrosis in SBCs, suggesting a common factor for the two different types of cell death. Mucoid matrix was reported to be more abundant in NSBCs than in SBCs, and appeared to occur more often in elder NSBC patients compared with younger NSBC patients. This indicates that it is produced in the later stages of tumorigenesis. In SBCs, several clinicopathologic parameters were found to be correlated with MIB-1 LI. Among them, increased age, recurrence, and nuclear pleomorphism were the only independent factors found to indicate a higher MIB-1 LI. No such parameters were found in NSBCs. However, in these lesions, prognosis was significantly poorer in those cases with nuclear pleomorphism compared with those without.
CONCLUSIONS: The results of the current study suggest that nuclear pleomorphism is a prognostic indicator in NSBCs. The proliferative ability of SBCs appears to be closely associated with patient age, clinical status (recurrence), and nuclear pleomorphism. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14584077     DOI: 10.1002/cncr.11756

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

Review 1.  Current therapeutic options and novel molecular markers in skull base chordomas.

Authors:  Filippo Gagliardi; Nicola Boari; Paola Riva; Pietro Mortini
Journal:  Neurosurg Rev       Date:  2011-10-18       Impact factor: 3.042

2.  The prognostic value of Ki-67, p53, epidermal growth factor receptor, 1p36, 9p21, 10q23, and 17p13 in skull base chordomas.

Authors:  Craig Horbinski; Gerard J Oakley; Kathleen Cieply; Geeta S Mantha; Marina N Nikiforova; Sanja Dacic; Raja R Seethala
Journal:  Arch Pathol Lab Med       Date:  2010-08       Impact factor: 5.534

Review 3.  Infantile clivus chordoma without clivus involvement: case report and review of the literature.

Authors:  D Kombogiorgas; E J St George; S Chapman; M English; G A Solanki
Journal:  Childs Nerv Syst       Date:  2006-03-25       Impact factor: 1.475

4.  Prognostic significance of immunohistochemical expression of VEGFR2 and iNOS in spinal chordoma.

Authors:  Reza Akhavan-Sigari; Michael Robert Gaab; Veit Rohde; Mehdi Abili; Helmut Ostertag
Journal:  Eur Spine J       Date:  2014-06-15       Impact factor: 3.134

Review 5.  Tumors of the osseous spine.

Authors:  Narayan Sundaresan; Stephano Boriani; Allen Rothman; Robert Holtzman
Journal:  J Neurooncol       Date:  2004 Aug-Sep       Impact factor: 4.130

Review 6.  The biological basis for modern treatment of chordoma.

Authors:  Roberto Jose Diaz; Michael D Cusimano
Journal:  J Neurooncol       Date:  2011-03-08       Impact factor: 4.130

7.  Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.

Authors:  R Akhavan-Sigari; M Abili; M R Gaab; V Rohde; N Zafar; P Emami; H Ostertag
Journal:  Neurosurg Rev       Date:  2014-10-17       Impact factor: 3.042

8.  Fascin expression in skull base chordoma: correlation with tumor recurrence and dura erosion.

Authors:  Ziyun Gao; Qiuhang Zhang; Feng Kong; Ge Chen; Mingchu Li; Hongchuan Guo; Jiantao Liang; Yuhai Bao; Feng Ling
Journal:  Med Oncol       Date:  2012-02-16       Impact factor: 3.064

9.  High expression of survivin in sacral chordoma.

Authors:  Chao Chen; Hui-Lin Yang; Kang-Wu Chen; Gen-Lin Wang; Jian Lu; Quan Yuan; Yong-Ping Gu; Zong-Ping Luo
Journal:  Med Oncol       Date:  2013-03-16       Impact factor: 3.064

Review 10.  Spine extra-osseous chordoma mimicking neurogenic tumors: report of three cases and review of the literatures.

Authors:  Jian Yang; Xinghai Yang; Wujun Miao; Qi Jia; Wei Wan; Tong Meng; Zhipeng Wu; Xiaopan Cai; Dianwen Song; Jianru Xiao
Journal:  World J Surg Oncol       Date:  2016-08-04       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.